Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 45; no. 3; p. 215
• Main Authors: Zhang, X S, Liu, B C, Du, X, Zhang, Y L, Xu, N, Liu, X L, Li, W M, Lin, H, Liang, R, Chen, C Y, Huang, J, Yang, Y F, Zhu, H L, Pan, L, Wang, X D, Li, G H, Liu, Z G, Zhang, Y Q, Liu, Z F, Hu, J D, Liu, C S, Li, F, Yang, W, Meng, L, Han, Y Q, Lin, L E, Zhao, Z Y, Tu, C Q, Zheng, C F, Bai, Y L, Zhou, Z P, Chen, S N, Qiu, H Y, Yang, L J, Sun, X L, Sun, H, Zhou, L, Liu, Z L, Wang, D Y, Guo, J X, Pang, L P, Zeng, Q S, Suo, X H, Zhang, W H, Zheng, Y J, Jiang, Q
• Format: Journal Article
• Language: Chinese
• Published: China 14.03.2024
• Subjects: Adult; China; Dasatinib - therapeutic use; Female; Humans; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Male; Middle Aged; Pyrimidines - therapeutic use; Retrospective Studies; Treatment Outcome; Tyrosine Kinase Inhibitors - therapeutic use; China; Leukemia, myeloid, chronic; Real-world study; Treatment status; Tyrosine kinase inhibitor; Multi-centre
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.cn121090-20231108-00255

To retrospectively analyze the treatment status of tyrosine kinase inhibitors (TKI) in newly diagnosed patients with chronic myeloid leukemia (CML) in China. Data of chronic phase (CP) and accelerated phase (AP) CML patients diagnosed from January 2006 to December 2022 from 77 centers, ≥18 years old, and receiving initial imatinib, nilotinib, dasatinib or flumatinib-therapy within 6 months after diagnosis in China with complete data were retrospectively interrogated. The choice of initial TKI, current TKI medications, treatment switch and reasons, treatment responses and outcomes as well as the variables associated with them were analyzed. 6 893 patients in CP ( =6 453, 93.6%) or AP ( =440, 6.4%) receiving initial imatinib ( =4 906, 71.2%), nilotinib ( =1 157, 16.8%), dasatinib ( =298, 4.3%) or flumatinib ( =532, 7.2%) -therapy. With the median follow-up of 43 ( 22-75) months, 1 581 (22.9%) patients switched TKI due to resistance ( =1 055, 15.3%), intolerance ( =248, 3.6%), pursuit of better efficacy ( =168,